NCT05853458 2026-04-07
HU-F-AIM
Novartis
Phase 4 Terminated
Clinical Trials
10 trialsNCT06093672 2026-03-25
GIV-IN-PV
Italfarmaco
Phase 3 Recruiting
NCT04116502 2024-11-18
MITHRIDATE
University of Birmingham
Phase 3 Recruiting
NCT01387763 2022-04-27
DALIAH
Odense University Hospital
Phase 3 Completed
NCT00928707 2019-10-31
PV
Italfarmaco
Phase 2 Completed
NCT01259856 2019-04-30
Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)
Icahn School of Medicine at Mount Sinai
Phase 3 Completed
NCT01243944 2019-03-06
Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)
Incyte Corporation
Phase 3 Completed
NCT01632904 2017-11-14
Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study
Incyte Corporation
Phase 3 Completed
NCT01949805 2016-11-28
PROUD-PV
AOP Orphan Pharmaceuticals AG
Phase 3 Completed
NCT01645124 2012-07-20
CYTO-PV
Consorzio Mario Negri Sud
Phase 3 Terminated